Cypress Biosciences About
Cypress: Cypress Bioscience Inc. (Cypress) (Nasdaq:
CYPB) is committed to being the innovator and leader in providing products for
the treatment of patients with Functional Somatic Syndromes and other related
chronic pain and central nervous system disorders. Functional Somatic Syndromes
refer to several related syndromes characterized more by symptoms, suffering and
disability than by disease-specific abnormalities that are found upon physical
examination and include many overlapping pain and psychiatric conditions such
as Fibromyalgia Syndrome,
or FMS, irritable
bowel syndrome, non-cardiac chest pain and interstitial cystitis, or chronic
pelvic pain. Product
Pipeline Data for Cypress Biosciences Cypress is developing
milnacipran for the treatment of Fibromyalgia
Syndrome. Milnacipran is the first of a new class of agents known as norepinephrine
serotonin reuptake inhibitors, or NSRIs, which increase the level of norepinephrine
more than they do serotonin. More
on Cypress
Biosciences: Key
Statistics for Cypress
Basic
Chart for Cypress